2025 Q4 -tulosraportti
86 päivää sitten
‧39 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | NON | ||
| 200 | SSWM | NON | ||
| 64 | NRD | NON | ||
| 466 | NRD | NON | ||
| 2 010 | NRD | SSWM |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·23 t sittenCURIUM AGREEMENT CHANGES EVERYTHING FOR CURASIGHT ☢️🔥 The partnership agreement with Curium gives Curasight direct access to existing global radiopharma infrastructure. Curium contributes not only with capital, but also with regulatory experience, global commercialization as well as production and distribution. The agreement includes milestone payments of up to 70 mio USD and double-digit royalties. In addition, Curium finances the entire uTRACE Phase II-program. Curium has the largest ownership stake in Curasight at 20%. This sends a significant signal about how much potential they see in the platform. The agreement with Curium is a huge advantage because Curasight does not start from scratch! 🔥 They are already directly connected to an existing global setup within isotopes, production, GMP, regulatory processes and distribution - something that takes many years and enormous investments to build up. And that is precisely what the market is increasingly starting to see. Theranostics is no longer just about strong biology and clinical data. In radiopharma, infrastructure has become at least as important. Isotopes are produced in relatively few places in the world, decay quickly and must be produced, transported and delivered almost in real-time. The entire value chain is complex, expensive and extremely difficult to scale quickly. BIG PHARMA POSITIONS ITSELF AGGRESSIVELY ☢️ The radiopharma market is expected to grow massively in the coming 5-10 years, and infrastructure can potentially become a real bottleneck. So strong data is therefore not enough if one cannot simultaneously produce and deliver the treatments globally. Already now, Novartis has started to experience capacity and delivery problems with both Pluvicto and Lutathera. That says a lot about how pressured the market is already starting to become. That is also why Big Pharma and the largest radiopharma companies are positioning themselves so aggressively right now. The battle is no longer just about who has the best data. RADIOPHARMA GOES FROM “SCIENCE” TO “INDUSTRIAL WAR” 🏭 The battle is not just about who has the best data. It is also about who can most quickly secure isotopes, production and global scaling. And this is precisely where the Curium agreement becomes so important. Curasight does not just get a partner. They get access to a large existing industrial engine in a market where infrastructure will probably become a major bottleneck in the coming years. This makes the platform significantly more attractive because a potential partner or buyer does not have to start building the entire infrastructure from scratch. As the theranostics market grows, it becomes crucial who can industrialize and scale globally. Big Pharma does not only get access to the uPAR platform and the data. They also get access to an existing setup for production, isotopes and global distribution from day one! And precisely that fact makes Curasight much more attractive in a future partnership or acquisition scenario! 🎯
·1 päivä sittenA minor detail, but Curasight has updated their "About us" subpage: The wording is more commercially oriented and emphasizes Utreat as Next-Gen. https://www.curasight.com/about-us/ (for comparison; the "About us" subpage from February 2026: https://web.archive.org/web/20260207020421/https://www.curasight.com/about-us/ Can this be read as optimization in connection with the upcoming SNMMI conference?·21 t sitten · MuokattuThey are redefining themselves as a clinical radiopharma platform with a theranostics focus! Great, we are truly on the right track! It will be interesting to see if, in connection with the Q1 report next week, which is a couple of days before the SNMMI conference, an FBM comes, so Andreas can talk about new uTREAT data at SNMMI. I find it very difficult to see Andreas going on the big international stage with old data!
·13 t sittenI asked Ulrich on April 16th at the investor seminar if there would be ongoing data from uTreat before they release Topline results. And the answer was that they expected an update before Topline. So it could actually be quite likely and good timing here before the conference.- ·2 päivää sitten · MuokattuuTRACE & uTREAT - FROM TARGET TO THERANOSTICS 📌 Both are built on uPAR as a common biological target and together they form the foundation of the integrated theranostics platform. First, patients are diagnosed and selected with uTRACE and then uTREAT is used for targeted therapeutic treatment. uTRACE HAS ALREADY VALIDATED uPAR IN HUMANS ☢️ uTRACE makes it possible to visualize aggressive cancer cells in humans via uPAR. PET-imaging is used to identify patients with high uPAR expression and thereby select which patients are best suited for targeted treatment. uTRACE has already been used in more than 450 patients across several clinical studies and aggressive cancer types such as glioblastoma, prostate cancer and head and neck cancer, distributed across 9 clinics in Europe. Early studies have shown that uPAR-PET can distinguish between less aggressive and more aggressive prostate cancer with high diagnostic precision and potentially reduce the need for repeated biopsies. uTRACE is now in Phase II studies in prostate cancer, where uPAR PET-imaging is being investigated as a non-invasive alternative or supplement to repeated biopsies in patients under active surveillance. The goal is more precise diagnostics and better assessment of disease aggressiveness, and recruitment is expected to be completed in H1 2026. uTREAT IS TO DELIVER STRONG CLINICAL SIGNALS 🔥 uTRACE makes it possible to identify and select patients before treatment, while uTREAT builds on the experience and data already established via uTRACE. The crucial factor will now be how high a tumor dose can be achieved, how precisely the radiation hits the tumors, and how consistent and reproducible the data proves to be across patients. Now it's about how strong and precise the therapeutic signal is. CURASIGHT STARTS WITH DIFFICULT CANCER TYPE 🧠 uTREAT is first tested in glioblastoma, one of the most aggressive and treatment-resistant cancer types ever, where the blood-brain barrier makes precise delivery of therapy extremely difficult. The interesting thing is not only the indication itself, but how Curasight has chosen to approach it. They could have maintained the original and more conservative Phase I design with a lower ambition level for tumor dose and fewer patients. Instead, they have chosen to adjust the target upwards to 100+ Gy, double the number of patients, and at the same time maintain the original timeline. This is convincing and testifies to significant confidence in the strength of the early signals. Early data has already shown clear and sustained tumor uptake of uTREAT in glioblastoma, where the signal remained visible for at least 24 hours after treatment. ☢️ Readout from the trial is expected in Q2 with topline results in H2. This is one of the most important data points in the entire case, as it will either confirm or reject the entire platform thesis around uPAR and theranostics, as the therapy part is ultimately crucial.💥 Data is King - we need to see it! ⚡
- ·2 päivää sitten · MuokattuDare we hope for some preliminary data from uTreat before/during the big conference at the end of next week? Or is it too optimistic to hope for? :) The waiting time feels long 😆·2 päivää sittenIt is the year's ultimately most important professional conference for CURAS. And Andreas is also a KOL (Key Opinion Leader). So he is COMPLETELY at the front of the bus! I cannot imagine Andreas showing up to such an event without updates on uTREAT (naturally within the rules regarding notification of price-sensitive information., but the frameworks are now quite broad). We will get the first indications when abstracts for SNMMI are published. Andres is on Tuesday the 02-06, at 11:00-12:15
·2 päivää sittenMy goodness, it's quiet here today 🤷♂️
·2 päivää sittenYep, it's very boring actually 😅 I simply cannot wait until there are updates from uTreat and/or uTrace
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
86 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 t sittenCURIUM AGREEMENT CHANGES EVERYTHING FOR CURASIGHT ☢️🔥 The partnership agreement with Curium gives Curasight direct access to existing global radiopharma infrastructure. Curium contributes not only with capital, but also with regulatory experience, global commercialization as well as production and distribution. The agreement includes milestone payments of up to 70 mio USD and double-digit royalties. In addition, Curium finances the entire uTRACE Phase II-program. Curium has the largest ownership stake in Curasight at 20%. This sends a significant signal about how much potential they see in the platform. The agreement with Curium is a huge advantage because Curasight does not start from scratch! 🔥 They are already directly connected to an existing global setup within isotopes, production, GMP, regulatory processes and distribution - something that takes many years and enormous investments to build up. And that is precisely what the market is increasingly starting to see. Theranostics is no longer just about strong biology and clinical data. In radiopharma, infrastructure has become at least as important. Isotopes are produced in relatively few places in the world, decay quickly and must be produced, transported and delivered almost in real-time. The entire value chain is complex, expensive and extremely difficult to scale quickly. BIG PHARMA POSITIONS ITSELF AGGRESSIVELY ☢️ The radiopharma market is expected to grow massively in the coming 5-10 years, and infrastructure can potentially become a real bottleneck. So strong data is therefore not enough if one cannot simultaneously produce and deliver the treatments globally. Already now, Novartis has started to experience capacity and delivery problems with both Pluvicto and Lutathera. That says a lot about how pressured the market is already starting to become. That is also why Big Pharma and the largest radiopharma companies are positioning themselves so aggressively right now. The battle is no longer just about who has the best data. RADIOPHARMA GOES FROM “SCIENCE” TO “INDUSTRIAL WAR” 🏭 The battle is not just about who has the best data. It is also about who can most quickly secure isotopes, production and global scaling. And this is precisely where the Curium agreement becomes so important. Curasight does not just get a partner. They get access to a large existing industrial engine in a market where infrastructure will probably become a major bottleneck in the coming years. This makes the platform significantly more attractive because a potential partner or buyer does not have to start building the entire infrastructure from scratch. As the theranostics market grows, it becomes crucial who can industrialize and scale globally. Big Pharma does not only get access to the uPAR platform and the data. They also get access to an existing setup for production, isotopes and global distribution from day one! And precisely that fact makes Curasight much more attractive in a future partnership or acquisition scenario! 🎯
- ·1 päivä sittenA minor detail, but Curasight has updated their "About us" subpage: The wording is more commercially oriented and emphasizes Utreat as Next-Gen. https://www.curasight.com/about-us/ (for comparison; the "About us" subpage from February 2026: https://web.archive.org/web/20260207020421/https://www.curasight.com/about-us/ Can this be read as optimization in connection with the upcoming SNMMI conference?·21 t sitten · MuokattuThey are redefining themselves as a clinical radiopharma platform with a theranostics focus! Great, we are truly on the right track! It will be interesting to see if, in connection with the Q1 report next week, which is a couple of days before the SNMMI conference, an FBM comes, so Andreas can talk about new uTREAT data at SNMMI. I find it very difficult to see Andreas going on the big international stage with old data!·13 t sittenI asked Ulrich on April 16th at the investor seminar if there would be ongoing data from uTreat before they release Topline results. And the answer was that they expected an update before Topline. So it could actually be quite likely and good timing here before the conference.
- ·2 päivää sitten · MuokattuuTRACE & uTREAT - FROM TARGET TO THERANOSTICS 📌 Both are built on uPAR as a common biological target and together they form the foundation of the integrated theranostics platform. First, patients are diagnosed and selected with uTRACE and then uTREAT is used for targeted therapeutic treatment. uTRACE HAS ALREADY VALIDATED uPAR IN HUMANS ☢️ uTRACE makes it possible to visualize aggressive cancer cells in humans via uPAR. PET-imaging is used to identify patients with high uPAR expression and thereby select which patients are best suited for targeted treatment. uTRACE has already been used in more than 450 patients across several clinical studies and aggressive cancer types such as glioblastoma, prostate cancer and head and neck cancer, distributed across 9 clinics in Europe. Early studies have shown that uPAR-PET can distinguish between less aggressive and more aggressive prostate cancer with high diagnostic precision and potentially reduce the need for repeated biopsies. uTRACE is now in Phase II studies in prostate cancer, where uPAR PET-imaging is being investigated as a non-invasive alternative or supplement to repeated biopsies in patients under active surveillance. The goal is more precise diagnostics and better assessment of disease aggressiveness, and recruitment is expected to be completed in H1 2026. uTREAT IS TO DELIVER STRONG CLINICAL SIGNALS 🔥 uTRACE makes it possible to identify and select patients before treatment, while uTREAT builds on the experience and data already established via uTRACE. The crucial factor will now be how high a tumor dose can be achieved, how precisely the radiation hits the tumors, and how consistent and reproducible the data proves to be across patients. Now it's about how strong and precise the therapeutic signal is. CURASIGHT STARTS WITH DIFFICULT CANCER TYPE 🧠 uTREAT is first tested in glioblastoma, one of the most aggressive and treatment-resistant cancer types ever, where the blood-brain barrier makes precise delivery of therapy extremely difficult. The interesting thing is not only the indication itself, but how Curasight has chosen to approach it. They could have maintained the original and more conservative Phase I design with a lower ambition level for tumor dose and fewer patients. Instead, they have chosen to adjust the target upwards to 100+ Gy, double the number of patients, and at the same time maintain the original timeline. This is convincing and testifies to significant confidence in the strength of the early signals. Early data has already shown clear and sustained tumor uptake of uTREAT in glioblastoma, where the signal remained visible for at least 24 hours after treatment. ☢️ Readout from the trial is expected in Q2 with topline results in H2. This is one of the most important data points in the entire case, as it will either confirm or reject the entire platform thesis around uPAR and theranostics, as the therapy part is ultimately crucial.💥 Data is King - we need to see it! ⚡
- ·2 päivää sitten · MuokattuDare we hope for some preliminary data from uTreat before/during the big conference at the end of next week? Or is it too optimistic to hope for? :) The waiting time feels long 😆·2 päivää sittenIt is the year's ultimately most important professional conference for CURAS. And Andreas is also a KOL (Key Opinion Leader). So he is COMPLETELY at the front of the bus! I cannot imagine Andreas showing up to such an event without updates on uTREAT (naturally within the rules regarding notification of price-sensitive information., but the frameworks are now quite broad). We will get the first indications when abstracts for SNMMI are published. Andres is on Tuesday the 02-06, at 11:00-12:15
- ·2 päivää sittenMy goodness, it's quiet here today 🤷♂️·2 päivää sittenYep, it's very boring actually 😅 I simply cannot wait until there are updates from uTreat and/or uTrace
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | NON | ||
| 200 | SSWM | NON | ||
| 64 | NRD | NON | ||
| 466 | NRD | NON | ||
| 2 010 | NRD | SSWM |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
86 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. | 5 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 t sittenCURIUM AGREEMENT CHANGES EVERYTHING FOR CURASIGHT ☢️🔥 The partnership agreement with Curium gives Curasight direct access to existing global radiopharma infrastructure. Curium contributes not only with capital, but also with regulatory experience, global commercialization as well as production and distribution. The agreement includes milestone payments of up to 70 mio USD and double-digit royalties. In addition, Curium finances the entire uTRACE Phase II-program. Curium has the largest ownership stake in Curasight at 20%. This sends a significant signal about how much potential they see in the platform. The agreement with Curium is a huge advantage because Curasight does not start from scratch! 🔥 They are already directly connected to an existing global setup within isotopes, production, GMP, regulatory processes and distribution - something that takes many years and enormous investments to build up. And that is precisely what the market is increasingly starting to see. Theranostics is no longer just about strong biology and clinical data. In radiopharma, infrastructure has become at least as important. Isotopes are produced in relatively few places in the world, decay quickly and must be produced, transported and delivered almost in real-time. The entire value chain is complex, expensive and extremely difficult to scale quickly. BIG PHARMA POSITIONS ITSELF AGGRESSIVELY ☢️ The radiopharma market is expected to grow massively in the coming 5-10 years, and infrastructure can potentially become a real bottleneck. So strong data is therefore not enough if one cannot simultaneously produce and deliver the treatments globally. Already now, Novartis has started to experience capacity and delivery problems with both Pluvicto and Lutathera. That says a lot about how pressured the market is already starting to become. That is also why Big Pharma and the largest radiopharma companies are positioning themselves so aggressively right now. The battle is no longer just about who has the best data. RADIOPHARMA GOES FROM “SCIENCE” TO “INDUSTRIAL WAR” 🏭 The battle is not just about who has the best data. It is also about who can most quickly secure isotopes, production and global scaling. And this is precisely where the Curium agreement becomes so important. Curasight does not just get a partner. They get access to a large existing industrial engine in a market where infrastructure will probably become a major bottleneck in the coming years. This makes the platform significantly more attractive because a potential partner or buyer does not have to start building the entire infrastructure from scratch. As the theranostics market grows, it becomes crucial who can industrialize and scale globally. Big Pharma does not only get access to the uPAR platform and the data. They also get access to an existing setup for production, isotopes and global distribution from day one! And precisely that fact makes Curasight much more attractive in a future partnership or acquisition scenario! 🎯
- ·1 päivä sittenA minor detail, but Curasight has updated their "About us" subpage: The wording is more commercially oriented and emphasizes Utreat as Next-Gen. https://www.curasight.com/about-us/ (for comparison; the "About us" subpage from February 2026: https://web.archive.org/web/20260207020421/https://www.curasight.com/about-us/ Can this be read as optimization in connection with the upcoming SNMMI conference?·21 t sitten · MuokattuThey are redefining themselves as a clinical radiopharma platform with a theranostics focus! Great, we are truly on the right track! It will be interesting to see if, in connection with the Q1 report next week, which is a couple of days before the SNMMI conference, an FBM comes, so Andreas can talk about new uTREAT data at SNMMI. I find it very difficult to see Andreas going on the big international stage with old data!·13 t sittenI asked Ulrich on April 16th at the investor seminar if there would be ongoing data from uTreat before they release Topline results. And the answer was that they expected an update before Topline. So it could actually be quite likely and good timing here before the conference.
- ·2 päivää sitten · MuokattuuTRACE & uTREAT - FROM TARGET TO THERANOSTICS 📌 Both are built on uPAR as a common biological target and together they form the foundation of the integrated theranostics platform. First, patients are diagnosed and selected with uTRACE and then uTREAT is used for targeted therapeutic treatment. uTRACE HAS ALREADY VALIDATED uPAR IN HUMANS ☢️ uTRACE makes it possible to visualize aggressive cancer cells in humans via uPAR. PET-imaging is used to identify patients with high uPAR expression and thereby select which patients are best suited for targeted treatment. uTRACE has already been used in more than 450 patients across several clinical studies and aggressive cancer types such as glioblastoma, prostate cancer and head and neck cancer, distributed across 9 clinics in Europe. Early studies have shown that uPAR-PET can distinguish between less aggressive and more aggressive prostate cancer with high diagnostic precision and potentially reduce the need for repeated biopsies. uTRACE is now in Phase II studies in prostate cancer, where uPAR PET-imaging is being investigated as a non-invasive alternative or supplement to repeated biopsies in patients under active surveillance. The goal is more precise diagnostics and better assessment of disease aggressiveness, and recruitment is expected to be completed in H1 2026. uTREAT IS TO DELIVER STRONG CLINICAL SIGNALS 🔥 uTRACE makes it possible to identify and select patients before treatment, while uTREAT builds on the experience and data already established via uTRACE. The crucial factor will now be how high a tumor dose can be achieved, how precisely the radiation hits the tumors, and how consistent and reproducible the data proves to be across patients. Now it's about how strong and precise the therapeutic signal is. CURASIGHT STARTS WITH DIFFICULT CANCER TYPE 🧠 uTREAT is first tested in glioblastoma, one of the most aggressive and treatment-resistant cancer types ever, where the blood-brain barrier makes precise delivery of therapy extremely difficult. The interesting thing is not only the indication itself, but how Curasight has chosen to approach it. They could have maintained the original and more conservative Phase I design with a lower ambition level for tumor dose and fewer patients. Instead, they have chosen to adjust the target upwards to 100+ Gy, double the number of patients, and at the same time maintain the original timeline. This is convincing and testifies to significant confidence in the strength of the early signals. Early data has already shown clear and sustained tumor uptake of uTREAT in glioblastoma, where the signal remained visible for at least 24 hours after treatment. ☢️ Readout from the trial is expected in Q2 with topline results in H2. This is one of the most important data points in the entire case, as it will either confirm or reject the entire platform thesis around uPAR and theranostics, as the therapy part is ultimately crucial.💥 Data is King - we need to see it! ⚡
- ·2 päivää sitten · MuokattuDare we hope for some preliminary data from uTreat before/during the big conference at the end of next week? Or is it too optimistic to hope for? :) The waiting time feels long 😆·2 päivää sittenIt is the year's ultimately most important professional conference for CURAS. And Andreas is also a KOL (Key Opinion Leader). So he is COMPLETELY at the front of the bus! I cannot imagine Andreas showing up to such an event without updates on uTREAT (naturally within the rules regarding notification of price-sensitive information., but the frameworks are now quite broad). We will get the first indications when abstracts for SNMMI are published. Andres is on Tuesday the 02-06, at 11:00-12:15
- ·2 päivää sittenMy goodness, it's quiet here today 🤷♂️·2 päivää sittenYep, it's very boring actually 😅 I simply cannot wait until there are updates from uTreat and/or uTrace
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | NON | ||
| 200 | SSWM | NON | ||
| 64 | NRD | NON | ||
| 466 | NRD | NON | ||
| 2 010 | NRD | SSWM |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt